Brief: Immunome Provides Update On Lead Oncology Candidate Targeting IL-38
23/05/2022 14:17
May 23 (Reuters) - Immunome Inc IMNM.O :
* IMMUNOME PROVIDES RESEARCH & DEVELOPMENT UPDATE ON LEAD
ONCOLOGY
CANDIDATE TARGETING IL-38
* IMMUNOME INC - ANTICIPATED IND FILING IN 2H 2022
* IMMUNOME INC - PROFILING OF IL-38 MRNA IN OVER 60 CANCER
TYPES
REVEALED NOTABLY HIGH FREQUENCY (60-80%) OF IL-38 EXPRESSION
Source text for Eikon: ID:nBw5HJP4ra
Further company coverage: IMNM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immunome
See all newsBrief: Immunome - Enters Amendment No. 4 To License Agreement With Bristol-Myers Squibb Company On Oct 2, 2026
US STOCKS ON THE MOVE-Cardinal Health, nVent, Acuity
U.S. STOCKS ON THE MOVE-Cardinal Health, Fervo Energy, Rocket Lab
U.S. STOCKS ON THE MOVE-Progress Software, Vicor Corp, Accenture
Immunome climbs as Stifel initiates coverage